228 results
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
peoples, persons with disabilities or members of visible minorities (referred to herein as “Designated Groups”). The Company recognizes the benefits … at the closing rate of CDN$1.00 = US$0.7378 at December 31, 2022.
Termination and Change of Control Benefits
The table below reflects amounts that would have
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
benefits of the Arrangement, the terms and conditions of the Arrangement Agreement, the timing of various steps to be completed in connection … of the Company may have certain interests in connection with the Arrangement or may receive certain collateral benefits (as such term is defined in MI 61
6-K
EX-99.3
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
, charges, encumbrances, claims, security interests and equities, together with all rights and benefits; (iii) has full power and authority to execute
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
March 31,
Short-term benefits
Stock-based compensation (recovery) expense – DSU plan
Stock option plan expense
BELLUS HEALTH INC.
Notes to Condensed
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
to realize the anticipated benefits of the transaction, the occurrence of any event that could give rise to termination of the transaction, and potential … in our studied patient population to the satisfaction of relevant regulatory agencies;
the function, potential benefits, tolerability profile
6-K
EX-99.1
g9frj8bqjj4c0t9n4ql
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
6-K
EX-99.1
vwqb06mfq
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.2
tkc2sm6 osgr6lepeh8w
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.1
qmiccy9mam5zj0
26 Apr 23
BELLUS Health Announces Meeting Updates
6:00pm
6-K
EX-99.1
q3y43ob 2nony
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
6-K
EX-99.1
6ftni8 zf7
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.2
1rc51bhfhofks
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
6-K
EX-99.1
n8q5 xcp0f
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.1
i04s1fbs31 8ryuk
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.2
frswcl37y4n11esng9
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
5s4dn
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
2wjqoupt3ji x2l
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
gzaeev quu
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
s1yoie0y al
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
yjs37gxdbf4tdcjnmh
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am